This study is to administer an influenza vaccine (AGRIPPAL S1/ MF 59, AGGRIPPAL S1) intranasally and determine safety, tolerability and initiate an antibody response. We plan to complete this study before the end of flu season.
Showing the most recent 10 out of 515 publications